La place des anticorps monoclonaux dans le traitement du cancer du sein

Abstract

Targeted therapies have led to significant progress in the treatment of breast cancer. They have made it possible to eliminate tumors and specifically target cancer cells, thus achieving increased therapeutic efficacy with fewer side effects. Today, a promising new approach to targeted therapy is gaining popularity: monoclonal antibodies, which have become a mainstay in the treatment of many cancers, particularly solid tumors. This study aims to evaluate the role of monoclonal antibodies in the treatment of breast cancer. To carry out this work, we opted for several studies based on the use of monoclonal antibodies in the treatment of this type of cancer to demonstrate their efficacy. These studies mainly include trastuzumab, pertuzumab, and sacituzumab-govitecan. The results of these studies clearly demonstrated that the benefits of these antibodies outweighed the risks, with the responses obtained strongly supporting continued treatment. The development of targeted therapies has opened up new perspectives in the treatment of breast cancer. Monoclonal antibodies have proven effective in this treatment, but research is still ongoing to expand their use and improve their outcomes.